Safety, tolerability and pharmacokinetics after single and multiple doses of preladenant (SCH420814) administered in healthy subjects
Authors:
- 7 June 2012
- journal article
- research article
- Published by Hindawi Limited in Journal of Clinical Pharmacy and Therapeutics
- Vol. 37 (5) , 578-587
Abstract
Preladenant (SCH420814, MK-3814) is a highly selective orally bioavailable non-methylxanthine adenosine 2A (A(2A) ) receptor antagonist under investigation for the treatment for Parkinson's disease. This study evaluated the safety, tolerability and pharmacokinetics of preladenant at single and multiple doses for the first time in humans. These were two randomized, double-blind, placebo-controlled, ascending-dose studies, one evaluating single rising preladenant doses (5-200 mg) compared with placebo and the other evaluating multiple rising preladenant doses (10-200 mg once daily over 10 days) compared with placebo. Safety was the primary end point of both studies. Safety evaluations, physical examinations, electrocardiograms, vital signs determinations and routine laboratory tests were performed before and at intervals throughout the studies. Blood samples were collected immediately before study drug administration and at various time points after dosing. Pharmacokinetic assessments of plasma preladenant and metabolites SCH434748 and SCH446637 were performed. One hundred and eight healthy adult men were randomly assigned in a 3 : 1 ratio to receive oral preladenant or matching placebo capsules under fasting conditions. Preladenant reached peak plasma concentrations in ∼1 h and then declined rapidly. Dose-related increases in exposure were observed up to 100 mg/day; accumulation was negligible at all doses. Transient mild increases in blood pressure occurred within a few hours after preladenant administration; blood pressure changes were neither cumulative nor dose-related nor associated with clinical sequelae. Preladenant was generally well tolerated up to the maximum dose tested (200 mg/day).Keywords
This publication has 22 references indexed in Scilit:
- Medical Treatment of Parkinson DiseaseNeurologic Clinics, 2009
- Adenosine, adenosine A2A antagonists, and Parkinson's diseaseParkinsonism & Related Disorders, 2009
- Functional organization of the basal ganglia: Therapeutic implications for Parkinson's diseaseMovement Disorders, 2008
- Adenosine A2A receptors and basal ganglia physiologyProgress in Neurobiology, 2007
- Blocking Striatal Adenosine A2A Receptors: A New Strategy for Basal Ganglia DisordersRecent Patents on CNS Drug Discovery, 2007
- Epidemiology of Parkinson's diseaseThe Lancet Neurology, 2006
- Cellular and behavioural effects of the adenosine A2a receptor antagonist KW‐6002 in a rat model of l‐DOPA‐induced dyskinesiaJournal of Neurochemistry, 2003
- Adenosine A2A receptor antagonists as new agents for the treatment of Parkinson's diseaseTrends in Pharmacological Sciences, 1997
- Opposing actions of adenosine A2a and dopamine D2 receptor activation on GABA release in the basal ganglia: Evidence for an A2a/D2 receptor interaction in globus pallidusSynapse, 1996
- Functional architecture of basal ganglia circuits: neural substrates of parallel processingTrends in Neurosciences, 1990